PEPG Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.370

-45.59%

-0.347

-62.23%

-0.352

-49.64%

Estimates Revision

Stock Price

Go Up

+37.22%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast PEPG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEPG is 10.00 USD with a low forecast of 3.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

3.00

Averages

10.00

High

20.00

Current: 0.000

Low

3.00

Averages

10.00

High

20.00

H.C. Wainwright

Andrew Fein

Buy

maintain

$18 -> $20

2025-11-13

Reason

H.C. Wainwright

Andrew Fein

Price Target

$18 -> $20

2025-11-13

maintain

Buy

Reason

H.C. Wainwright analyst Andrew Fein raised the firm's price target on PepGen to $20 from $18 and keeps a Buy rating on the shares. A new U.S. composition of matter patent for PGN-EDODM1 securing exclusivity into the 2040s reinforces the durability of its myotonic dystrophy type 1 franchise, the analyst tells investors.

H.C. Wainwright

Andrew Fein

Buy

maintain

$12 -> $18

2025-10-28

Reason

H.C. Wainwright

Andrew Fein

Price Target

$12 -> $18

2025-10-28

maintain

Buy

Reason

H.C. Wainwright analyst Andrew Fein raised the firm's price target on PepGen (PEPG) to $18 from $12 and keeps a Buy rating on the shares. The firm believes Novartis' (NVS) acquisition of Avidity (RNA) "has reshaped sentiment across the neuromuscular oligonucleotide space." PepGen's recent rally still leaves the stock at a "steep discount" to peers despite delivering "best-in-class" myotonic dystrophy type 1 data, the analyst tells investors in a research note.

H.C. Wainwright

Buy

maintain

$8 -> $12

2025-09-25

Reason

H.C. Wainwright

Price Target

$8 -> $12

2025-09-25

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on PepGen to $12 from $8 and keeps a Buy rating on the shares. The company reported 53.7% mean splicing correction at 15 mg/kg in the FREEDOM single dose study, the highest level disclosed in myotonic dystrophy type 1 patients to date, the analyst tells investors in a research note. The firm says one patient experienced a transient, reversible renal biomarker elevation that although resolved without intervention, indicates that the program \"might not be out of the woods yet.\" However, PepGen's nearly 54% correction sets a new benchmark and \"strongly suggests that repeat dosing could yield clinically meaningful functional benefit,\" contends H.C. Wainwright.

Guggenheim

Debjit Chattopadhyay

initiated

2025-09-09

Reason

Guggenheim

Debjit Chattopadhyay

Price Target

2025-09-09

initiated

Reason

Guggenheim analyst Debjit Chattopadhyay initiated coverage of PepGen with a Buy rating and $6 price target.

Guggenheim

initiated

2025-09-09

Reason

Guggenheim

Price Target

2025-09-09

initiated

Reason

As previously reported, Guggenheim initiated coverage of PepGen with a Buy rating and $6 price target. The firm believes the stock \"could trade higher by 5x to 10x over the next three quarters\" following clarity from the ongoing Single Ascending Dose/Multiple Ascending Dose studies in Myotonic Dystrophy Type 1, but if the SAD/MAD data underwhelm it would expect management will return residual cash to shareholders. Key upcoming clinical readouts include 15 mg/kg SAD data to be presented on October 11 and 5 mg/kg MAD data during Q1, notes the analyst, who is \"optimistic\" about the company's ability to demonstrate clinically meaningful improvement in splicing and other biomarkers.

H.C. Wainwright

Buy

downgrade

$14 -> $8

2025-05-29

Reason

H.C. Wainwright

Price Target

$14 -> $8

2025-05-29

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on PepGen to $8 from $14 and keeps a Buy rating on the shares after the company announced it is planning to discontinue the PGN-EDO51 program given the failure to achieve meaningful dystrophin expression. The decision is a prudent one, not only from the efficacy point of view but also from the safety hurdles that the program encountered during the course of the study, the analyst tells investors in a research note. H.C. Wainwright believes "encouraging" splicing data along with trend in clinical improvement can see a potential acquisition bid for PepGen, given the growing interest in myotonic dystrophy type 1.

Valuation Metrics

The current forward P/E ratio for PepGen Inc (PEPG.O) is -5.20, compared to its 5-year average forward P/E of -2.70. For a more detailed relative valuation and DCF analysis to assess PepGen Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.70

Current PE

-5.20

Overvalued PE

-1.17

Undervalued PE

-4.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.37

Current EV/EBITDA

-3.35

Overvalued EV/EBITDA

0.17

Undervalued EV/EBITDA

-2.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 294713.82% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 294713.82% over the last month.

Sold

Bought

PEPG News & Events

Events Timeline

No data

News

5.0

2025-12-09Newsfilter

PepGen Appoints New Chief Business Officer with 160,000 Stock Options Grant

2.0

2025-12-08Benzinga

Meihua International Medical Technologies, Fly-E Group, and Other Major Stocks Decline in Pre-Market Trading on Monday

5.0

2025-12-08Newsfilter

PepGen Appoints Joseph Vittiglio as Chief Business and Legal Officer

People Also Watch

Frequently Asked Questions

What is PepGen Inc (PEPG) stock price today?

The current price of PEPG is 6.47 USD — it has decreased -4.01 % in the last trading day.

What is PepGen Inc (PEPG)'s business?

PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.

What is the price predicton of PEPG Stock?

What is PepGen Inc (PEPG)'s revenue for the last quarter?

PepGen Inc revenue for the last quarter amounts to -18.65M USD, decreased -19.49 % YoY.

What is PepGen Inc (PEPG)'s earnings per share (EPS) for the last quarter?

PepGen Inc. EPS for the last quarter amounts to -19356000.00 USD, decreased -20.01 % YoY.

What changes have occurred in the market's expectations for PepGen Inc (PEPG)'s fundamentals?

The market is revising No Change the revenue expectations for PEPG for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 37.22%.

How many employees does PepGen Inc (PEPG). have?

PepGen Inc (PEPG) has 81 emplpoyees as of January 10 2026.

What is PepGen Inc (PEPG) market cap?

Today PEPG has the market capitalization of 444.80M USD.